Streetbeat News

NVAX

Novavax, Inc.

https://www.novavax.com

Industry

Biotechnology

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Open

7.14

Mkt cap

1.2B

Volume

High

7.33

P/E Ratio

-3.01

52-wk high

23.86

Low

6.81

Div yield

N/A

52-wk low

3.53

The FDA has approved updated COVID-19 vaccines by Moderna and Pfizer-BioNTech to counter current viral strains, including the omicron variant. The vaccines are expected to be ready by fall. Novavax, another company in the race to update its COVID-19 vaccine, saw its shares fall almost 13% after the approval of Pfizer's and Moderna's vaccines.

Portfolio Pulse from AJ Fabino

September 11, 2023 | 8:57 pm

Novavax CEO announced that the company has signed contracts for the broad distribution of its updated COVID-19 vaccine.

Portfolio Pulse from Bill Haddad

September 11, 2023 | 8:04 pm

Novavax has announced that it does not expect its updated Covid-19 vaccine to be authorized before the CDC advisors meet on Tuesday, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 6:19 pm

UK regulators have approved an updated COVID-19 vaccine by Pfizer and BioNTech that targets the Omicron XBB.1.5 subvariant. Moderna and Novavax have also created versions of their shots that target this variant. The U.S. plans to deploy all three vaccines in the fall season. Pfizer's updated vaccine elicited a strong antibody response in a preclinical study in mice with the highly mutated BA.2.86 subvariant of the coronavirus. Moderna's updated vaccine is expected to be effective against the BA.2.86 subvariant and is expected to be available by early October.

Portfolio Pulse from Upwallstreet

September 06, 2023 | 8:39 pm

The FDA plans to approve updated versions of the Covid booster as early as Friday, targeting the XBB.1.5 omicron subvariant. The timeline for authorization could extend into next week. The FDA is considering granting the boosters a full approval license instead of an emergency use authorization. Pfizer and Moderna have indicated the list price for the vaccines will be $110 to $130 per dose. Novavax’s vaccine, available through emergency use authorization, will continue to be covered.

Portfolio Pulse from Happy Mohamed

September 06, 2023 | 7:02 pm

Novavax shares are trading higher due to the increase in COVID cases in the US, which has positively affected vaccine stocks recently.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 3:56 pm

U.S. stocks ended in red with the Dow Jones falling by nearly 200 points or 0.56%. Novavax shares surged by 10.23% due to increasing COVID cases in the US. Zscaler’s stock appreciated by 2.75% after reporting a 43% YoY increase in its Q4 revenue. Digital Brands Group's stock jumped 31.56% after announcing the closure of its offering for the issuance and sale of shares. Asana’s stock showed a marginal increase of 0.05% after Q2 results surpassed market expectations. Tesla’s stock climbed by 4.69% after Ark Invest's CEO reiterated her $2,000 price target for Tesla by 2027.

Portfolio Pulse from Benzinga Neuro

September 06, 2023 | 1:41 am

Shares of Novavax, Inc. (NASDAQ:NVAX) traded higher amid rising COVID-19 cases in the US, which has lifted vaccine stocks recently. Novavax shares have risen over 20% since the beginning of the month, tied to rising hospitalization and death levels due to a new COVID-19 wave. The effectiveness of COVID tests against new variants and the potential match of 2023 boosters for BA.2.86's mutations remain uncertain.

Portfolio Pulse from Ryan Gustafson

September 05, 2023 | 8:36 pm

Novavax shares are trading higher due to the increase in COVID cases in the US, which has boosted vaccine stocks recently.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 7:31 pm

Several stocks experienced significant movement in Monday's mid-day session. Notable gainers included Mobile Infrastructure Corporation (BEEP), GD Culture Group Limited (GDC), Hersha Hospitality Trust (HT), and Hawaiian Electric Industries, Inc. (HE). On the other hand, AgileThought, Inc. (AGIL), NovoCure Limited (NVCR), Faraday Future Intelligent Electric Inc. (FFIE), and Heliogen, Inc. (HLGN) were among the biggest losers.

Portfolio Pulse from Lisa Levin

August 28, 2023 | 5:52 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.